166 related articles for article (PubMed ID: 19659610)
1. Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer.
Yamashita H; Takahashi S; Ito Y; Yamashita T; Ando Y; Toyama T; Sugiura H; Yoshimoto N; Kobayashi S; Fujii Y; Iwase H
Cancer Sci; 2009 Nov; 100(11):2028-33. PubMed ID: 19659610
[TBL] [Abstract][Full Text] [Related]
2. Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
Motomura K; Ishitobi M; Komoike Y; Koyama H; Nagase H; Inaji H; Noguchi S
Oncology; 2010; 79(1-2):55-61. PubMed ID: 21071990
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial.
Bartlett JM; Brookes CL; Robson T; van de Velde CJ; Billingham LJ; Campbell FM; Grant M; Hasenburg A; Hille ET; Kay C; Kieback DG; Putter H; Markopoulos C; Kranenbarg EM; Mallon EA; Dirix L; Seynaeve C; Rea D
J Clin Oncol; 2011 Apr; 29(12):1531-8. PubMed ID: 21422407
[TBL] [Abstract][Full Text] [Related]
4. Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer.
Yamashita H; Nishio M; Toyama T; Sugiura H; Kondo N; Kobayashi S; Fujii Y; Iwase H
Endocr Relat Cancer; 2008 Sep; 15(3):755-63. PubMed ID: 18550720
[TBL] [Abstract][Full Text] [Related]
5. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
[TBL] [Abstract][Full Text] [Related]
6. Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.
Toi M; Saji S; Masuda N; Kuroi K; Sato N; Takei H; Yamamoto Y; Ohno S; Yamashita H; Hisamatsu K; Aogi K; Iwata H; Takada M; Ueno T; Saji S; Chanplakorn N; Suzuki T; Sasano H
Cancer Sci; 2011 Apr; 102(4):858-65. PubMed ID: 21231986
[TBL] [Abstract][Full Text] [Related]
7. The potential clinical benefit of targeting androgen receptor (AR) in estrogen-receptor positive breast cancer cells treated with Exemestane.
Amaral C; Augusto TV; Almada M; Cunha SC; Correia-da-Silva G; Teixeira N
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165661. PubMed ID: 31891807
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
Generali D; Buffa FM; Berruti A; Brizzi MP; Campo L; Bonardi S; Bersiga A; Allevi G; Milani M; Aguggini S; Papotti M; Dogliotti L; Bottini A; Harris AL; Fox SB
J Clin Oncol; 2009 Jan; 27(2):227-34. PubMed ID: 19064988
[TBL] [Abstract][Full Text] [Related]
9. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
[TBL] [Abstract][Full Text] [Related]
10. Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy.
Kurozumi S; Yamaguchi Y; Matsumoto H; Kurosumi M; Hayashi SI; Fujii T; Horiguchi J; Shirabe K; Inoue K
PLoS One; 2019; 14(5):e0217279. PubMed ID: 31112577
[TBL] [Abstract][Full Text] [Related]
11. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Arnedos M; Drury S; Afentakis M; A'Hern R; Hills M; Salter J; Smith IE; Reis-Filho JS; Dowsett M
Ann Oncol; 2014 Mar; 25(3):605-610. PubMed ID: 24525703
[TBL] [Abstract][Full Text] [Related]
12. AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
O'Hara J; Vareslija D; McBryan J; Bane F; Tibbitts P; Byrne C; Conroy RM; Hao Y; Gaora PÓ; Hill AD; McIlroy M; Young LS
Clin Cancer Res; 2012 Jun; 18(12):3305-15. PubMed ID: 22550166
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
Ellis MJ; Suman VJ; Hoog J; Lin L; Snider J; Prat A; Parker JS; Luo J; DeSchryver K; Allred DC; Esserman LJ; Unzeitig GW; Margenthaler J; Babiera GV; Marcom PK; Guenther JM; Watson MA; Leitch M; Hunt K; Olson JA
J Clin Oncol; 2011 Jun; 29(17):2342-9. PubMed ID: 21555689
[TBL] [Abstract][Full Text] [Related]
14. High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer.
Endo Y; Toyama T; Takahashi S; Sugiura H; Yoshimoto N; Iwasa M; Kobayashi S; Fujii Y; Yamashita H
Int J Clin Oncol; 2011 Oct; 16(5):512-8. PubMed ID: 21431343
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
Bundred NJ; Cramer A; Morris J; Renshaw L; Cheung KL; Flint P; Johnson R; Young O; Landberg G; Grassby S; Turner L; Baildam A; Barr L; Dixon JM
Clin Cancer Res; 2010 Mar; 16(5):1605-12. PubMed ID: 20179229
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
[TBL] [Abstract][Full Text] [Related]
17. An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER
Amaral C; Correia-da-Silva G; Almeida CF; Valente MJ; Varela C; Tavares-da-Silva E; Vinggaard AM; Teixeira N; Roleira FMF
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677847
[TBL] [Abstract][Full Text] [Related]
18. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.
Yamamoto M; Hosoda M; Nakano K; Jia S; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Cancer Sci; 2014 Jan; 105(1):81-8. PubMed ID: 24118529
[TBL] [Abstract][Full Text] [Related]
19. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
[TBL] [Abstract][Full Text] [Related]
20. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.
Johnston SR; Kilburn LS; Ellis P; Dodwell D; Cameron D; Hayward L; Im YH; Braybrooke JP; Brunt AM; Cheung KL; Jyothirmayi R; Robinson A; Wardley AM; Wheatley D; Howell A; Coombes G; Sergenson N; Sin HJ; Folkerd E; Dowsett M; Bliss JM;
Lancet Oncol; 2013 Sep; 14(10):989-98. PubMed ID: 23902874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]